Novel Radiotherapy Approaches Show Promise in Limited-Stage Small Cell Lung Cancer Treatment
• Recent clinical evidence has established that both once-daily and twice-daily radiotherapy regimens show comparable efficacy in limited-stage small cell lung cancer treatment, eliminating the need for further fractionation studies.
• Advanced techniques including gated radiotherapy, adaptive planning, and FLASH radiotherapy are emerging as promising approaches to improve treatment precision and reduce damage to healthy tissue.
• FLASH radiotherapy's ultra-rapid delivery system, capable of administering 60 Gy in one second, shows potential for better preserving immune system function during treatment.
DURECT's Larsucosterol Shows Promise in Alcohol-Associated Hepatitis Treatment
• DURECT Corporation's larsucosterol demonstrates potential in treating alcohol-associated hepatitis (AH) by reducing mortality rates in U.S. patients.
• A Phase 3 trial, agreed upon with the FDA, will assess larsucosterol's efficacy with a 90-day survival primary endpoint, aiming for topline data within two years.
• Larsucosterol targets DNA methyltransferases, epigenetic enzymes linked to hypermethylation in AH, offering a novel approach to managing the condition.
• Data from the AHFIRM Phase 2b trial supports the Phase 3 design, showing significant mortality reduction with larsucosterol in U.S. patients.
© Copyright 2025. All Rights Reserved by MedPath